Soleno TherapeuticsSLNO
SLNO
About: Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Employees: 92
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
212% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 25
100% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 24
16% more funds holding
Funds holding: 142 [Q3] → 165 (+23) [Q4]
2% less call options, than puts
Call options by funds: $120M | Put options by funds: $123M
4% less capital invested
Capital invested by funds: $2.38B [Q3] → $2.29B (-$85M) [Q4]
2.86% less ownership
Funds ownership: 121.22% [Q3] → 118.37% (-2.86%) [Q4]
11% less funds holding in top 10
Funds holding in top 10: 9 [Q3] → 8 (-1) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$81
8%
upside
Avg. target
$109
46%
upside
High target
$145
94%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler Yasmeen Rahimi 25% 1-year accuracy 6 / 24 met price target | 94%upside $145 | Overweight Maintained | 24 Apr 2025 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 125 / 331 met price target | 34%upside $100 | Buy Reiterated | 15 Apr 2025 |
Stifel James Condulis 67% 1-year accuracy 2 / 3 met price target | 44%upside $108 | Buy Maintained | 28 Mar 2025 |
Guggenheim Debjit Chattopadhyay 22% 1-year accuracy 5 / 23 met price target | 8%upside $81 | Buy Maintained | 28 Mar 2025 |
Laidlaw & Co. Yale Jen 33% 1-year accuracy 2 / 6 met price target | 40%upside $105 | Buy Maintained | 27 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET
REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.
Neutral
GlobeNewsWire
2 weeks ago
Soleno Therapeutics Announces VYKAT(TM) XR Launch
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company's treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025.
Positive
Zacks Investment Research
1 month ago
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
Positive
Investors Business Daily
1 month ago
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher
Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed. The post Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher appeared first on Investor's Business Daily.
Positive
Benzinga
1 month ago
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
The U.S. Food and Drug Administration (FDA) on Wednesday approved Soleno Therapeutics, Inc.'s SLNO Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
Neutral
GlobeNewsWire
1 month ago
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th , at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
Neutral
GlobeNewsWire
2 months ago
Soleno Therapeutics to Participate in Upcoming February Investor Conferences
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February:
Neutral
GlobeNewsWire
4 months ago
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million.
Neutral
GlobeNewsWire
5 months ago
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.
Neutral
GlobeNewsWire
5 months ago
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.
Charts implemented using Lightweight Charts™